Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Lennar Corporation — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Lennar Corporation trades at $73.9 (market cap $17.81B). The key difference: Lennar Corporation is far larger — about 2× Kymera Therapeutics Inc. Common Stock's market cap, and Lennar Corporation pays a 2.67% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Lennar Corporation for 67 Days on average.
| KYMR | LEN | |
|---|---|---|
Market Cap | $8.87B | $17.81B |
Volume | 779,107 | 4,102,017 |
Sector | Health | Consumer Cyclical |
52-Week High | $127.31 | $133.13 |
52-Week Low | $55.80 | $73.53 |
Typical Hold Time | 0 Days | 67 Days |
Enterprise Value | $8.26B | $22.23B |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lennar (LEN) trades at $73.53, down 1.5% on the day, with a bearish technical signal and recent earnings misses. The homebuilder shows declining revenue and profit margins, with 2025 revenue at $34.19B and net income of $2.08B. Valuation metrics appear attractive with P/E of 14.19 and P/B of 0.83, but cash flow trends show negative net cash flow of -$1.16B in 2025. Berkshire Hathaway has been accumulating shares, building an 11.2% stake as of October 2026.
Lennar presents a value opportunity with below-book valuation and strong institutional interest, but faces headwinds from declining profitability, negative cash flow, and housing market challenges. The stock trades below the $77.38 consensus price target, offering potential upside if operational improvements materialize, though execution risks and macroeconomic pressures remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
